UPDATE 1-EU agency backs IDM Pharma's bone cancer drug; shrs up - Reuters UK

UPDATE 1-EU agency backs IDM Pharma's bone cancer drug; shrs up Reuters UK, UK - Nov 18, 2008 O: Quote, Profile, Research) said advisors to the European Commission recommended the approval of its experimental treatment for a rare bone cancer, ... IDM Pharma shares jump on cancer drug ruling CNNMoney.com IDM Pharma Gains on Drug's Positive European Review (Update3) Bloomberg IDM Pharma Scores on EU Ruling Zacks.com MarketWatch - Pharmacy Europe all 30 news articles

Study Identifies Causes of Bone Loss in Breast Cancer Survivors - DG News

Study Identifies Causes of Bone Loss in Breast Cancer Survivors DG News - 2 hours ago Among 64 breast cancer patients referred to a bone health clinic, 78% had at least 1other cause of bone loss, including vitamin D deficiency, ... Causes Of Bone Loss In Breast Cancer Survivors Include Cancer ... Science Daily (press release) all 9 news articles

Amgen Drug for Lung Cancer Suspended After Deaths (Update3) - Bloomberg

Amgen Drug for Lung Cancer Suspended After Deaths (Update3) Bloomberg - 1 hour ago Motesanib and the bone treatment denosumab are at the forefront of Amgen's efforts to become a major provider of cancer medicines. ...

Two-Time Cancer Survivor's Tale of Thanksgiving - MarketWatch

Two-Time Cancer Survivor's Tale of Thanksgiving MarketWatch - 1 hour ago They will also reconstruct the patient's thumbs using remnants of bone and skin from his chest and groin areas. The patient will be placed in a hyperbaric ...

CTS: Proton Therapy Reduces Bone Marrow Toxicity in Lung Cancer ... - MedPage Today

CTS: Proton Therapy Reduces Bone Marrow Toxicity in Lung Cancer ... MedPage Today, NJ - Nov 18, 2008 18 -- Non-small-cell lung cancer patients on chemotherapy who undergo treatment with proton beam radiation appear to suffer less bone marrow toxicity than ...